Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.40 |
| ▸ | HNF4A | P41235 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.38 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.38 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31071979 | 1.00 | AKR1B1 (0.46) | AKR1B1PTGDR2TDP1CXCL8HNF4A | |
| SCHEMBL7968570 | 0.88 | AKR1B1 (0.53) | AKR1B1PTGDR2TDP1CXCL8PTGS2 | |
| SCHEMBL3633503 | 0.85 | PTGDR2 (0.54) | AKR1B1PTGDR2TDP1CXCL8PTGS2 | |
| SCHEMBL2550680 | 0.83 | PTGDR2 (0.56) | AKR1B1PTGDR2TDP1CXCL8PTGS2 | |
| Hydrochloric Acid SCHEMBL11528572 | 0.82 | PTGDR2 (0.55) | AKR1B1PTGDR2TDP1CXCL8PTGS2 | |
| SCHEMBL21767469 | 0.82 | KDM4E (0.41) | PDE10A | |
| SCHEMBL31072042 | 0.82 | KDM4E (0.41) | PDE10A | |
| SCHEMBL12281735 | 0.81 | SLC6A2 (0.57) | AKR1B1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22156301 | 0.80 | PDE1A (0.41) | PDE10ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1156415 | 0.75 | SLC6A2 (0.43) | AKR1B1PTGDR2ASPHKDM8SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHR¿DINGER, LLC | 2024-11-14 | — | — | US | disclosed |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4086254-A1 | INTEGRIN INHIBITORS | Morphic Therapeutic, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11021480-B2 | Inhibiting (α-V)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| CN-112805001-A | Inhibition of alpha v beta 6 integrins | 莫菲克医疗股份有限公司 | 2021-05-14 | — | — | CN | disclosed |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHRÖDINGER, LLC | 2020-12-10 | — | — | US | disclosed |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2020047239-A1 | INHIBITING αV β6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| EP-3617206-A1 | INTEGRIN INHIBITORS | Morphic Therapeutic, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | AKR1B1 4194/4885PTGDR2 2222/4885TDP1 4549/4885 |
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | AKR1B1 3994/4885PTGDR2 1758/4885TDP1 4473/4885 |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | AKR1B1 3994/4885PTGDR2 1758/4885TDP1 4473/4885 |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | AKR1B1 3994/4885PTGDR2 1758/4885TDP1 4473/4885 |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | AKR1B1 3994/4885PTGDR2 1758/4885TDP1 4473/4885 |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | AKR1B1 3994/4885PTGDR2 1758/4885TDP1 4473/4885 |
| US-11021480-B2 | Inhibiting (α-V)(β-6) integrin | ITGB6, ITGA6, ITGAV | AKR1B1 4194/4885PTGDR2 2222/4885TDP1 4549/4885 |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | AKR1B1 4194/4885PTGDR2 2222/4885TDP1 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.